Singapore markets close in 3 minutes
Straits Times Index
3,294.68 -2.21 (-0.07%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,198.05 +25.90 (+0.32%) Bitcoin USD
59,318.14 +1,466.67 (+2.54%) CMC Crypto 200
1,285.02 +8.04 (+0.63%)
Merck & Co., Inc. (MRK)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 128.80 |
| Open | 128.61 |
| Bid | 128.31 x 1000 |
| Ask | 129.08 x 900 |
| Day's range | 127.99 - 129.69 |
| 52-week range | 99.14 - 133.10 |
| Volume | |
| Avg. volume | 8,217,444 |
| Market cap | 324.886B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 142.51 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.08 (2.40%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Business Wire
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J., May 01, 2024--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer
- Business Wire
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
RAHWAY, N.J., April 29, 2024--Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
- Business Wire
Merck Announces First-Quarter 2024 Financial Results
RAHWAY, N.J., April 25, 2024--Merck Announces First-Quarter 2024 Financial Results
© 2024 Yahoo. All rights reserved.